Weighing in

Henderson, Shirley
April 2000
Advertising Age;4/3/2000, Vol. 71 Issue 14, pS4
Trade Publication
Reports on the sales performance of the anti-obesity prescription drug market in the United States in 1999. Sales performance of Hoffmann-La Roche's Xenical and Knoll Pharmaceutical Co.'s Meridia; Advertising campaigns created for the drugs; Predicted sales for the years 2000 and 2001.


Related Articles

  • WOLFE: STRICTER CONTROL OF DTC NEEDED. Dickinson, James G. // Medical Marketing & Media;Apr2002, Vol. 37 Issue 4, p34 

    Reports developments related to direct-to-consumer advertising of drugs in the U.S. as of April 2002. Increase in the direct-to-consumer promotions; Failure of Hoffmann-LaRoche Inc. to include statements of side effects on the Xeloda advertisement; Preference of drug companies to use network...

  • Honesty is the Best Policy. Hallahan, Mary; Mordock, Jeff // Pharmaceutical Executive;Nov99, Vol. 19 Issue 11, p87 

    Provides information on the direct-to-consumer advertising for Hoffmann-La Roche's diet drug, Xenical. Budget for the campaign; Analysis of Xenical advertisements; Goal of the campaign.

  • Roche Looks for New Spin on Xenical.  // Pharmaceutical Executive;May2000, Vol. 20 Issue 5, p154 

    Announces the search of Hoffman-La Roche for an advertising agency to promote its antiobesity drug Xenical. Revenues generated by sales of the drug for the first quarter of 2000; Advertising expenditures of the company for the drug; Media buys that the company initiated.

  • Roche Kicks Off Review for Xenical. McMains, Andrew // Adweek Western Edition;04/17/2000, Vol. 50 Issue 16, p86 

    Focuses on a review of Xenical advertising account launched by pharmaceutical company Roche Laboratories in 2000. Advertising spending of the company in 1999; Factor affecting the sales of the drug; Features of the campaign.

  • Obesity drugs trim ads. Goetzl, David // Advertising Age;8/13/2001, Vol. 72 Issue 33, p10 

    The article reports on the decision of obesity drug manufacturers Hoffmann-La Roche and Abbott Pharmaceuticals to discontinue direct-to-consumer (DTC) advertising for their products. Hoffmann-La Roche's new campaign, launched in February 2001, which was designed in part to divert attention from...

  • DEA move could kill some DTC ads. Dickinson, James G. // Medical Marketing & Media;Feb99, Vol. 34 Issue 2, p36 

    Reports on the potential impact of a United States Drug Enforcement Complaint's complaint against Knoll Pharmaceutical Co.'s drug advertisement on the promotional activity for controlled substances.

  • Xenical account moves to Y&R.  // Medical Marketing & Media;Aug2000, Vol. 35 Issue 8, p24 

    Reports that Hoffmann-La Roche has moved its account for Xenical to Y&R Advertising. Previous handling of the account by Lowe Consumer Healthcare; Awarding of the first professional promotion for Xenical to Sudler and Hennessey.

  • Latelines.  // Drug Topics;1/17/2000, Vol. 144 Issue 2, p7 

    Presents news briefs on to the pharmaceutical industry in the United States (US) as of January 17, 2000. Increase in spending of shoppers in 1999 for holiday gifts; Approval of the US Food and Drug Administration for Tamiflu, a medication manufactured by Hoffmann-La Roche for influenza; Request...

  • First DTC drug ads of 2000 promote a wide assortment. Levy, Sandra // Drug Topics;2/7/2000, Vol. 144 Issue 3, p120 

    Focuses on the DTC drug campaign of several pharmaceutical companies in the United States in 2000. Information on Searle/Pfizer's television portion of its DTC campaign for its arthritis drug, Celebrex; Campaign of Roche Laboratories for its Tamiflu and Rocephin drugs; Television commercial for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics